Stratatech Awarded $3.5 Million to Continue Development of Infection-Fighting Skin Substitute
11/16/2010 11:20:11 AM
MADISON, Wis.--(BUSINESS WIRE)--Stratatech Corp., a privately-held regenerative medicine company, today announced that it has been awarded a $3.5 million Fast-Track SBIR grant to expand the development of its anti-infective living human skin substitute. Stratatech was one of only a few companies that received an award from the National Institute of Allergy and Infectious Diseases (NIAID) under a special request for applications to foster partnerships to develop therapeutics and diagnostics for drug-resistant bacteria. For this project, Stratatech is partnering with the Armed Forces Institute of Pathology, the University of Wisconsin-Madison and the Waisman Clinical Biomanufacturing Facility.
comments powered by